Metabolic Syndrome and the Risk of Breast Cancer and Subtypes by Race, Menopause and BMI by Dibaba, Daniel T. et al.
University of Kentucky
UKnowledge
Epidemiology Faculty Publications Epidemiology
9-1-2018
Metabolic Syndrome and the Risk of Breast Cancer
and Subtypes by Race, Menopause and BMI
Daniel T. Dibaba
University of Kentucky, daniel.dibaba@uky.edu
Dejana Braithwaite
Georgetown University
Tomi Akinyemiju
University of Kentucky, tomiakin@uky.edu
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/epidemiology_facpub
Part of the Endocrinology, Diabetes, and Metabolism Commons, and the Epidemiology
Commons
This Article is brought to you for free and open access by the Epidemiology at UKnowledge. It has been accepted for inclusion in Epidemiology Faculty
Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Dibaba, Daniel T.; Braithwaite, Dejana; and Akinyemiju, Tomi, "Metabolic Syndrome and the Risk of Breast Cancer and Subtypes by
Race, Menopause and BMI" (2018). Epidemiology Faculty Publications. 39.
https://uknowledge.uky.edu/epidemiology_facpub/39
Metabolic Syndrome and the Risk of Breast Cancer and Subtypes by Race, Menopause and BMI
Notes/Citation Information
Published in Cancers, v. 10, issue 9, 299, p. 1-13.
© 2018 by the authors. Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons
Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Digital Object Identifier (DOI)
https://doi.org/10.3390/cancers10090299
This article is available at UKnowledge: https://uknowledge.uky.edu/epidemiology_facpub/39
cancers
Article
Metabolic Syndrome and the Risk of Breast Cancer
and Subtypes by Race, Menopause and BMI
Daniel T. Dibaba 1,2 ID , Dejana Braithwaite 3 and Tomi Akinyemiju 1,2,*
1 Department of Epidemiology, University of Kentucky, Lexington, KY 40508, USA; daniel.dibaba@uky.edu
2 Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA
3 Department of Oncology, Georgetown University, Washington, DC 20015, USA;
dejana.braithwaite@georgetown.edu
* Correspondence: tomiakin@uky.edu; Tel.: +1-859-323-1147
Received: 12 July 2018; Accepted: 29 August 2018; Published: 1 September 2018


Abstract: The objective of this study was to investigate the association of metabolic syndrome (MetS)
with the risk of invasive breast cancer and molecular subtypes across race, menopause, and body
mass index (BMI) groups. We examined the association of metabolic syndrome and its components
with risk of invasive breast cancer among 94,555 female participants of the National Institute of
Health-American Association of Retired Persons (NIH-AARP) Diet and Health Study, accounting for
ductal carcinoma in situ as a competing risk. Cox proportional hazard regression with the Fine and
Gray method was used to generate hazard ratios (HR) and 95% confidence intervals (CI) adjusting
for baseline sociodemographic, behavioral, and clinical covariates. During a mean follow-up of
14 years, 5380 (5.7%) women developed breast cancer. Overall, MetS at baseline was associated with
a 13% increased risk of breast cancer compared to women without MetS (HR: 1.13, 95% CI: 1.00,
1.27); similar estimates were obtained among postmenopausal women (HR: 1.14, 95% CI: 1.01, 1.29).
MetS was associated with a slight but non-significantly increased risk of breast cancer among those
with both normal weight and overweight/obesity, and those with estrogen receptor positive breast
cancer subtype. In the NIH-AARP cohort, MetS was associated with an increased risk of breast cancer.
Further studies are needed to definitively evaluate the association of MetS with triple negative breast
cancer subtypes across all levels of BMI.
Keywords: metabolic syndrome; breast cancer incidence; obesity; metabolic health; NIH-AARP
1. Introduction
Breast cancer remains the most common cancer type among women globally, with an estimated
266,120 new cases of invasive breast cancer diagnosed in the U.S. in 2018 [1–3]. Epidemiological
studies indicate that although black women in the U.S. have a relatively lower incidence of breast
cancer compared with white women, they experience significantly worse prognosis, including a
higher risk of aggressive breast cancer subtypes and higher mortality [4,5]. Treatment strategies
for breast cancer have improved significantly in the past few decades, but primary prevention
strategies to reduce the incidence of breast cancer have been limited by inconsistent information
regarding the role of modifiable risk factors, such as obesity and metabolic syndrome (MetS). MetS
is a cluster of interrelated abnormalities that include central obesity, insulin resistance, dyslipidemia,
and hypertension. Individual components of MetS, specifically central obesity [6,7], diabetes [8], and
hypertension [9,10], have been associated with increased risk of breast cancer in prior studies, although
the underlying biological mechanism remain unclear. Research also indicates an independent positive
association between MetS and breast cancer incidence [11–13], aggressive cancer phenotypes [14–16],
and distant metastasis [17]. However, it is currently accepted that breast cancer consists of several
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biologically distinct subtypes with potentially distinct etiology. For instance, among premenopausal
women, obesity is associated with lower risk of hormone receptor-positive (estrogen receptor (ER)+
and progesterone receptor (PR)+) breast cancer, but higher risk of hormone receptor-negative breast
cancer [18,19]; whereas among postmenopausal women, obesity is associated with higher risk of
hormone receptor-positive breast cancer [20]. Most prior studies evaluating the association between
MetS and breast cancer risk are based on case-control studies with limited racial diversity and sample
size, and evidence from prospective studies in the U.S. is limited. Given the increasing epidemic
of obesity and associated metabolic conditions in the U.S. and globally, it is critically important to
determine the nature of the association between MetS and breast cancer risk by subtype, and across
levels of race, menopausal status, and BMI.
This study examines the association of MetS and its components with risk of breast cancer and
subtypes by levels of body mass index (BMI), menopausal status, and race in a prospective cohort of
older women after adjusting for sociodemographic, behavioral, and clinical covariates.
2. Methods
2.1. Study Participants
Data were obtained from the National Institute of Health–American Association of Retired
Persons (NIH-AARP) Diet and Health Study. Participants in the NIH-AARP were recruited at
baseline in 1995–1996 with a questionnaire mailed to 3.5 million AARP members aged 50–71 years
residing in California, Florida, Louisiana, New Jersey, North Carolina, Pennsylvania, or in one of two
metropolitan areas (Atlanta, Georgia; and Detroit, Michigan) in the U.S. [21]. To maximize recruitment
of minority populations, smaller states and metropolitan areas with a large minority population
were included. The NIH-AARP cohort has been described in greater detail elsewhere [22]. Baseline
data on demographics, lifestyle, and behavioral characteristics were collected and cancer outcomes
were ascertained from state cancer registries with at least 90–95% complete case ascertainment in the
NIH-AARP cohort [22]. Of 566,398 participants that consented and were included in the NIH-AARP
cohort, participants were excluded from the current analysis due to one or more exclusion criteria:
(1) male gender, (2) self-reported cancer diagnosis at baseline, (3) self-reported poor health or end-stage
renal disease (a recommended primary exclusion criteria), (4) died of cancer at baseline or data obtained
from proxy respondents, (5) did not return Risk Factors Questionnaire (RFQ), and (6) missing values
for covariates; leaving 94,555 participants for final analyses (Figure 1). Participants with missing values
were not significantly different from those with complete data based on BMI (p = 0.117); however,
those with missing values were older, had lower education, and were more likely to be black (p-values
< 0.05). The study was limited to only blacks and whites, as other races (4.3% of total) did not remain
in the analyses due to substantial (>65%) missing values in the components of MetS, breast cancer
incidence, or covariates. The Special Studies Institutional Review Board (IRB) of the U.S. National
Cancer Institute approved the NIH-AARP Diet and Health Study (protocol number: OH95CN025) [23].
2.2. Main Exposure
In line with the joint harmonized criteria [24], MetS is defined as the presence of at least
three components at baseline including: (1) high waist circumference (WC) >88 cm for women,
(2) dyslipidemia or self-reported history of elevated cholesterol level, (3) high blood pressure or
self-reported history of hypertension, and (4) self-reported history of diabetes. Systolic and diastolic
blood pressure, high-density lipoprotein (HDL), triglyceride, and blood glucose were not objectively
measured in the NIH-AARP Diet and Health study; however, high blood pressure (hypertension),
elevated cholesterol level, and type 2 diabetes were self-reported based on whether a doctor had ever
told the participant that they had the condition at baseline.
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Figure 1. Participant selection process.
2.3. Main Outcome
Incident invasive breast cancer was ascertained through probabilistic linkage with the cancer
registry databases from the aforementioned eight original states, and three additional states (Arizona,
Nevada, and Texas) in order to capture participants who moved to those states during follow-up [25].
The linkages were based on names, address, sex, social security number, and date of birth from the
baseline questionnaire. Dates of diagnosis were obtained from the cancer registries; details have been
published elsewhere [23]. Censoring occurred on the date of breast cancer diagnosis, death, loss to
follow-up, or 31 December 2011, whichever occurred first.
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2.4. Study Covariates
The analysis included baseline data on age, race (non-Hispanic whites, or non-Hispanic blacks),
region (West, South, Midwest, or Northwest), BMI (kg/m2), and education (less than high school,
high school/General Education Development (GED), some college, and ≥college). BMI was derived
from weight and height variables and categorized into normal BMI (18.5 kg/m2 ≤ BMI < 25 kg/m2)
and overweight or obese (BMI ≥ 25 kg/m2). Other baseline study covariates included behavioral
characteristics such as physical activity (physical activity in the past 12 months: never, rarely, 1–3 times
per month, 1–2 times per week, 3–4 times per week, 5 or more times per week, or unknown), smoking
(yes/no), hormonal therapy use (never used, currently using, formerly used or unknown). Additional
covariates were family history of breast cancer, ovary status (both ovaries removed, both ovaries intact,
or other surgery), and hysterectomy status.
2.5. Statistical Analysis
Distribution of study variables by breast cancer status was examined using the chi-squared test or
Fisher’s exact test. To examine the association between MetS and risk of breast cancer adjusting for a
priori specified confounders, the Cox proportional hazard regression with the Fine and Gray method
was used to account for ductal carcinoma in situ as a competing risk [26]. The models were adjusted
for baseline covariates including age, BMI, race, physical activity, education, smoking, region, family
history of breast cancer, ovary status, current hormonal therapy use, and hysterectomy. Multicollinearity
between covariates was checked using the variance inflation factor (VIF) method—all VIFs were <2,
and the proportional hazard assumption was checked using the cumulative martingale residuals and
Kolmogorov-type supremum test [27]. In separate models, the exposure of interest i.e., MetS (yes vs. no),
each MetS component, the cumulative number of MetS components, and 4 separate combinations of
three individual components were tested in relation to breast cancer incidence, comparing women
with MetS or individual components to those without. Additionally, stratified analysis by BMI, race,
and menopausal status were conducted, with formal tests of effect modification using the maximum
likelihood ratio test and the Breslow-Day-Taron test [28]. Risk of breast cancer by hormone receptor
subtypes was examined using logistic regression to compare ER− vs. ER+ subtypes (case only analysis),
and to compare each subtype with non-cancer cases. Results are presented as hazard ratios or odds
ratios (ORs) and 95% confidence intervals (CI). A p-value ≤ 0.05 was considered statistically significant,
and for interactions terms, p-values ≤ 0.1 were considered statistically significant. All analyses were
conducted using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
3. Results
Among 94,555 study participants (3802 black and 90,753 white women) followed up for an average
of 14 years (SD: 3.6 years), 5380 participants developed breast cancer (166 blacks and 5214 whites).
Compared to participants without breast cancer (Table 1), breast cancer cases were more likely to occur
in whites (97% vs. 96%), in those with a college education (38% vs. 34%), overweight or obese (BMI ≥
25: 17% vs. 16%), current hormonal therapy users (53% vs. 47%), and more likely to have a family
history of breast cancer (18% vs. 12%).
After adjusting for baseline covariates (Table 2), MetS was associated with a marginally higher
risk of overall breast cancer incidence (HR: 1.13, 95% CI: 1.00, 1.27). Having a single component of
MetS was associated with a 14% increased risk of breast cancer (HR: 1.14, 95% CI: 1.03, 1.25), and the
risk generally increased with the number of MetS components. The risk of breast cancer was 45%
higher for participants with four components of MetS compared with none (HR: 1.45, 95% CI: 0.99,
2.13). In addition, each additional component of MetS present was associated with a 10% increased
risk of breast cancer (HR: 1.10, 95% CI: 1.06, 1.14, p < 0.0001). There was a marginally higher but
non-significant association between MetS and overall breast cancer among participants with normal
BMI (HR: 1.04, 95% CI: 0.69, 1.58) and overweight/obese (HR: 1.08, 95% CI: 0.95, 1.23). However,
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higher number of MetS components remained associated with an increased risk of breast cancer in
both groups, by 11% in those with normal BMI (HR: 1.11, 95% CI: 1.03, 1.19; p = 0.004) and 6% in those
with overweight/obesity (HR: 1.06, 95% CI: 1.00, 1.12; p = 0.043). Elevated cholesterol was consistently
associated with overall breast cancer risk (HR: 1.06, 95% CI: 1.01, 1.12) and across BMI groups (Table 2),
in normal BMI (HR: 1.13, 95% CI: 1.04, 1.23), and overweight/obese (HR: 1.03, 95% CI: 0.96, 1.11)
women. High blood pressure was associated with increased risk among overweight/obese women
(HR: 1.08, 95% CI: 1.01, 1.16). No significant association was observed among black women; however,
a higher number of MetS components was significantly associated with breast cancer risk among
white women.
Table 1. Baseline characteristics of the participants by breast cancer incidence during follow-up.
Study Characteristics Total Breast Cancer No Breast Cancer p-Value
N (%) N (col%) N (col%)
Ethnicity
White 90,753 (96.0) 5214 (96.9) 85,539 (95.9)
0.0003Black 3802 (4.0) 166 (3.1) 3636 (4.1)
Age at entry
50–59 35,805 (37.9) 1899 (35.3) 33,906 (38)
<0.000160–69 55,638 (58.8) 3317 (61.7) 52,321 (58.7)
70–79 3112 (3.3) 164 (3.0) 2948 (3.3)
Education
<High school 4058 (4.3) 189 (3.5) 3869 (4.3)
<0.0001
High school or GED 33,226 (35.1) 1762 (32.8) 31,464 (35.3)
Some college 24,563 (26.0) 1401 (26) 23,162 (26)
≥College 32,708 (34.6) 2028 (37.7) 30,680 (34.4)
Menopausal status
Premenopausal 3693 (3.9) 196 (3.6) 3497 (3.9)
0.304Postmenopausal 90,662 (96.1) 5174 (96.4) 85,488 (96.1)
BMI
<18.5 1450 (1.5) 2344 (43.7) 39,752 (44.7)
0.047
18.5–24.9 42,096 (44.6) 1719 (32) 28,617 (32.2)
25.0–29.9 30,336 (32.2) 776 (14.5) 12,174 (13.7)
30.0–34.9 12,950 (13.7) 460 (8.6) 7039 (7.9)
≥35 7499 (8.0) 556 (8.4) 6943 (7.9)
Metabolic syndrome
Yes (%) 4956 (5.2) 293 (5.4) 4663 (5.2) 0.091
Current hormone therapy
Yes (%) 44,387 (46.9) 2863 (53.2) 41,524 (46.6) <0.0001
Family history of breast cancer
Yes (%) 11,949 (12.6) 951 (17.7) 10,998 (12.3) <0.0001
Note: p-values were obtained from Chi-square test or Fisher exact test. Abbreviations: BMI, body mass index;
col, column.
MetS or individual components were not significantly associated with ER− compared with ER+
hormone-receptor subtype overall or among post-menopausal women in case-only analysis (Table 3),
or in analysis comparing each subtype with non-cancer cases (data not shown).
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Table 2. Hazard ratios (HRs) a and 95% confidence intervals (CI) for metabolic syndrome (MetS) and
breast cancer risk by body mass index (BMI) and race.
N (Events) All 94,555 (5380) b Black 3802 (166) b White 90,753 (5214) b
Overall c
MetS 1.13 (1.00, 1.27) 0.79(0.43, 1.43) 1.10 (0.97, 1.25)
Components
High WC 1.13 (1.05, 1.21) 0.65 (0.42, 1.02) 1.11 (1.02, 1.21)
Elevated Cholesterol 1.06 (1.01, 1.12) 1.03 (0.76, 1.39) 1.08 (1.02, 1.14)
High blood pressure 1.11 (1.04, 1.17) 1.28 (0.92, 1.78) 1.08 (1.02, 1.15)
Diabetes 1.03 (0.92, 1.16) 0.83 (0.52, 1.34) 1.02 (0.90, 1.15)
Number of MetS Components
0 (Ref) 1.00 1.00 1.00
1 1.14 (1.03, 1.25) 1.08 (0.56, 2.11) 1.13 (1.03, 1.25)
2 1.26 (1.13, 1.40) 0.78 (0.38, 1.62) 1.25 (1.12, 1.39)
3 1.30 (1.12, 1.51) 0.84 (0.36, 1.99) 1.29 (1.10, 1.51)
4 1.45 (0.99, 2.13) 0.51 (0.06, 4.11) 1.48 (1.00, 2.19)
Normal BMI
MetS 1.04 (0.69, 1.58) NE 1.10 (0.73, 1.67)
Components
High WC 0.97 (0.82, 1.16) NE 1.00 (0.84, 1.19)
Elevated Cholesterol 1.13 (1.04, 1.23) 1.12 (0.59, 2.15) 1.13(1.04, 1.23)
High blood pressure 1.09 (0.99, 1.20) 1.22 (0.64, 2.31) 1.09 (0.99, 1.20)
Diabetes 0.91 (0.68, 1.22) 0.28 (0.04, 1.99) 0.95 (0.71, 1.28)
Number of MetS Components
0 (Ref)
1 1.15 (1.02, 1.29) 0.87 (0.32, 2.33) 1.15 (1.02, 1.29)
2 1.27 (1.09, 1.48) 0.88 (0.27, 2.86) 1.27 (1.09, 1.49)
3 1.15 (0.75, 1.78) NE 1.21 (0.78, 1.87)
4 1.16 (0.16, 8.40) NE 1.47 (0.20, 10.62)
Overweight/Obese
MetS 1.08 (0.95, 1.23) 0.83 (0.45, 1.52) 1.09 (0.96, 1.24)
Components
High WC 1.13 (1.03, 1.25) 0.73 (0.44, 1.20) 1.15 (1.04, 1.27)
Elevated Cholesterol 1.03 (0.96, 1.11) 0.96 (0.67, 1.37) 1.04 (0.96, 1.12)
High blood pressure 1.08 (1.01, 1.16) 1.31 (0.88, 1.95) 1.07 (1.00, 1.16)
Diabetes 1.01 (0.89, 1.16) 0.93 (0.56, 1.55) 1.02 (0.89, 1.17)
Number of MetS Components
0 (Ref)
1 1.10 (0.92, 1.32) 1.24 (0.48, 3.24) 1.10 (0.92, 1.32)
2 1.18 (0.99, 1.41) 0.74 (0.28, 1.95) 1.20 (1.00, 1.44)
3 1.24 (1.01, 1.53) 0.95 (0.33, 2.76) 1.25 (1.01, 1.55)
4 1.35 (0.89, 2.05) 0.57 (0.06, 5.06) 1.40 (0.92, 2.15)
a Models were adjusted for age, race (in non-race stratified models only), BMI (in non-BMI stratified models
only), education, region, physical activity, smoking, marital status, family history of breast cancer, ovary status,
hysterectomy, hormonal therapy use, and ovary status × BMI interaction (in non-BMI stratified models only). b
N = number of incident breast cancers. The interaction between MetS and BMI was not significant, p = 0.410.
Bold indicates statistically significant at the 0.05 alpha level. Abbreviations: BMI, body mass index; MetS,
metabolic syndrome; NE, non-estimable; Ref, referent; WC, waist circumference. Women without MetS or respective
components were the referent.
MetS was associated with higher risk of breast cancer in postmenopausal (HR: 1.14, 95% CI:
1.01, 1.29) but not in pre-menopausal (HR: 0.83, 95% CI: 0.38, 1.78) women (Table 4). High waist
circumference (HR: 1.12, 95% CI: 1.04, 1.20), elevated cholesterol (HR: 1.07, 95% CI: 1.01, 1.13), and
high blood pressure (HR: 1.11, 95% CI: 1.05, 1.17) were each significantly associated with higher risk
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of breast cancer among postmenopausal women, and there was a clear trend in increased risk with
increased number of MetS components among postmenopausal women. When further stratified by
BMI (Figure 2), the lack of association with MetS among pre-menopausal women remained, regardless
of BMI. In postmenopausal women, elevated cholesterol (HR: 1.14, 95% CI: 1.05–1.24) remained
associated with increased risk of breast cancer among women with normal BMI, whereas high waist
circumference (HR: 1.13, 95% CI: 1.02, 1.25) and high blood pressure (HR: 1.08, 95% CI: 1.00–1.16) were
associated with a higher risk of breast cancer in women classified as overweight/obese.
Table 3. Odds ratios (ORs) a and 95% confidence intervals for MetS and breast cancer risk by hormone
receptor subtype δ and menopausal status (case only).
Overall Postmenopausal Premenopausal
N (Events) ER− vs. ER+4392 (685) §
ER− vs. ER+
4212 (664)
ER− vs. ER+
169 (21)
MetS 0.88 (0.60, 1.28) 0.97 (0.66, 1.43) NE
Components
High WC 0.71 (0. 57, 0.88) 0.82 (0.62, 1.08) 0.15 (0.02, 1.52)
Elevated Cholesterol 1.12 (0.95, 1.33) 1.09 (0.92, 1.29) 2.04 (0.53, 7.88)
High blood pressure 0.93 (0.78, 1.11) 0.98 (0.82, 1.17) 0.44 (0.09, 2.22)
Diabetes 0.98 (0.68, 1.41) 1.02 (0.71, 1.48) 2.92 (0.11, 78.03)
Number of MetS Components
0 Ref Ref Ref
1 1.05 (0.78, 1.41) 1.00 (0.74, 1.34) NE
2 0.85 (0.61, 1.18) 0.94 (0.67, 1.33) NE
3 0.85 (0.53, 1.36) 0.99 (0.61, 1.63) NE
4 1.18 (0.38, 3.63) 1.50 (0.48, 4.71) NE
Adjusted covariates included age, race, BMI, marital status, family history of breast cancer, hormone therapy
use, and hysterectomy. a The odds of ER- were compared to the odds of ER+. δ ER status only due to limited
sample sizes for HER2 receptor status. § N is the overall ER− and ER+ sample size, and events are only ER− cases.
Abbreviations: ER+, estrogen receptor positive; ER−, estrogen receptor negative; NE, non-estimable.
Table 4. Hazard ratios (HRs) a and 95% confidence intervals for MetS and breast cancer risk by
menopausal status.
N (Events) Postmenopausal90,662 (5174) b
Premenopausal
3693 (196) b
MetS 1.14 (1.01, 1.29) 0.83 (0.38, 1.78)
Components
High WC 1.12 (1.04, 1.20) 1.31 (0.90, 1.90)
Elevated Cholesterol 1.07 (1.01, 1.13) 0.88 (0.65, 1.19)
High blood pressure 1.11 (1.05, 1.17) 1.14 (0.82, 1.59)
Diabetes 1.05 (0.93, 1.18) 0.60 (0.22, 1.63)
Number of MetS Components
0 (Ref) 1.00 1.00
1 1.15 (1.0, 1.27) 0.79 (0.48, 1.30)
2 1.26 (1.14, 1.41) 1.01 (0.59, 1.78)
3 1.32 (1.13, 1.53) 0.70 (0.28, 1.75)
4 1.44 (0.97, 2.12) 2.00 (0.23, 17.74)
a Models were adjusted for age, race, BMI, region, physical activity, smoking, marital status, family history of breast
cancer, ovary status, hysterectomy, hormonal therapy use, and ovary status × BMI interaction. b Case = number
of incident breast cancer; N = sample size. Bold indicates statistically significant at the 0.05 alpha level. Women
without MetS or respective components were the referent.
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5174) 
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High blood pressure, diabetes and 
elevated cholesterol  
1.04 (0.80, 1.34) 1.02 (0.79, 1.32) 0.60 (0.08, 4.42) 
High blood pressure, elevated 
cholesterol and high WC 
1.12 (0.97, 1.29) 1.09(0.94, 1.26) 0.79 (0.34, 1.79) 
Models were adjusted for age, race, BMI, education, region, physical activity, smoking, marital status, 
family history of breast cancer, ovary status, hysterectomy, hormonal therapy use, and ovary status 
Figure 2. Association of metabolic syndrome (MetS) and its components with the risk of breast cancer
by menopausal and obesity status. Abbreviations: BMI, body mass index; Chol, elevated cholesterol;
DM, diabetes; HBP, high blood pressure; HR, hazard ratio; WC, high waist circumference. The HR
for the association of MetS with breast cancer risk was non-estimable for normal BMI premenopausal
women. The models are adjusted for age, race, BMI, region, physical activity, smoking, marital status,
family history of breast cancer, ovary status, hysterectomy, and hormonal therapy use.
To assess which cluster of MetS components was most strongly associated with breast cancer risk,
we evaluated every possible combination compared with those without each combination in relation
to overall breast cancer incidence, and observed that clusters including high waist circumference were
associated with statistically non-significant higher risk, ranging from 12 to 15% (Table 5).
Table 5. Association between combinations of MetS components and breast cancer risk by menopausal
status (HR, 95% CI).
MetS Component Combinations Overall(N = 94,555, Cases = 5380) b
Post nopausal
(N = 90,662, Cases = 5174)
Pr enopausal
(N = 3693, Cases = 196)
High blood pressure, high WC and diabetes 1.15 (0.93, 1.43) 1.11 (0.90, 1.38) 1.18 (0.28, 4.92)
Elevated cholesterol, diabetes, and high WC 1.15 (0.86, 1.53) 1.10 (0.82, 1.48) 1.14 (0.15, 8.87)
igh blood pressure, diabetes and
elevated cholesterol 1.04 (0.80, 1.34) 1.02 (0.79, 1.32) 0.60 (0.08, 4.42)
High blood pressure, elevated cholesterol
and high WC 1.12 (0.97, 1.29) 1.09(0.94, 1.26) 0.79 (0.34, 1.79)
Models were adjusted for age, race, BMI, education, region, physical activity, smoking, marital status, family history
of breast cancer, ovary status, hysterectomy, hormonal therapy use, and ovary status × BMI interaction. Women
without the respective combination of the components were the referent in each analysis. b cases = number of
incident breast cancer. Abbreviations: WC, waist circumference.
4. Discussion
In the large NIH-AARP prospective cohort, MetS was significantly associated with increased
risk of breast cancer overall, and the risk increased as the number of MetS components present at
baseline increased. These associations were observed only among post-menopausal women. Among
the four distinct clusters of MetS components, all three clusters associated with a notable increased
risk of breast cancer included high waist circumference and other combinations of diabetes and high
blood pressure.
Other studies observed an increased risk of breast cancer among individuals with MetS or
metabolically healthy, overweight, or obese [29], and a recent meta-analysis of observational studies
reported a 56% increased risk of breast cancer among those with MetS [30]. Among the five studies
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included in the meta-analysis, two studies [31,32] were nested case-control, whereas the other three
were longitudinal [33–35] in design. The U.S. study included in the meta-analysis [33] was relatively
small and focused on postmenopausal women in the Women’s Health Initiative clinical trial, whereas
three other included studies [31,32,34] were conducted in Europe—one of them being relatively
large [34] and one was conducted among the Japanese population [35]. The result of another
meta-analysis of observational studies [36], two of which overlap with the previous meta-analysis [30],
indicated a borderline non-significant 11% increased risk of breast cancer in postmenopausal women
with MetS in cohort studies, a two-fold increased risk in studies with other study designs, and a 52%
increased risk overall. Another study from a European cohort observed that MetS was associated
with a lower risk of breast cancer in premenopausal women [34]. A recent cohort study among
postmenopausal women in the Sister Study in the U.S. found normal-weight women with one or
more components of MetS had about 26% higher risk of breast cancer [29]. Other case-control [11,37]
and case-cohort studies [38] have also shown strong associations between MetS and breast cancer.
Consistent with these prior studies, we observed a modestly higher risk of breast cancer among
women with MetS or its individual components; however, these results were only significant among
post-menopausal white women. Our study adds unique insights to this growing area of research,
especially showing that MetS was associated with a marginally lower risk of ER− compared to ER+
breast cancer among American women, and highlighting the central role of high waist circumference
in MetS-associated risk. A similarly higher ER+ breast cancer risk was found among overweight or
obese postmenopausal women with one or more components of MetS in the Sister Study [29].
There are several biological mechanisms underlying this increased breast cancer risk among
individuals with MetS, and studies suggest that the risk associated with multiple MetS components
may be synergistic, such that the combined effect is worse than that of individual components [39–41].
Although we did not observe direct evidence of synergistic effects of multiple components in the
present study, the biological mechanisms linking MetS components and breast cancer risk are likely
interconnected. For instance, central obesity and increased adiposity in MetS likely contribute to
breast cancer risk through alterations in hormonal regulation leading to over-production of estrogen
and intense aromatase activity, ultimately resulting in breast tissue proliferation [42]. We observed
higher breast cancer risk among post-menopausal women with normal BMI and overweight/obesity,
suggesting that strategies focused on reducing central obesity (regardless of BMI) after menopause
may be a key prevention strategy for breast cancer. The reduced risk of ER− breast cancer associated
with MetS also suggests that obesity may lead to increased endogenous estrogen post-menopause that
may contribute to tumorigenesis. Larger studies are needed to definitively evaluate this hypothesis.
Another potential mechanism involves insulin resistance and hyperinsulinemia, which are
common features of MetS. Hyperinsulinemia increases the bioavailability of insulin-like growth factor
2 (IGF2) through its effect on growth hormone in liver [42]. Both insulin resistance and IGF2 affect
energy metabolism, cell differentiation and proliferation, and suppression of apoptosis [43]. Adipokine
production is elevated in MetS [44,45], which has also been implicated in increased risk of breast
cancer [46,47]. Other pathways include low-grade chronic inflammation [48] and cholesterol [49]. In a
highly proliferative microenvironment such as breast cancer, cholesterol is required for the formation
of new cell membranes [49]. It is likely that the mechanisms that regulate cholesterol uptake are altered
in those with MetS, and among the three independent clusters of MetS components associated with the
higher risk of breast cancer in the current study, high cholesterol was present in two. Another probable
pathway is 27HC, which is a cholesterol metabolite that promotes estrogen receptor (ER)-positive breast
cancer in vitro, and an ER agonist that could inhibit the liver X receptor-a regulator of cholesterol [49].
Future studies are needed to test the potential biological synergy between cholesterol and endogenous
estrogen leading to increased risk of specific breast cancer subtypes. Since high cholesterol is clinically
manageable, if found to play a synergetic role with central obesity and/or estrogen regulation to
increase breast cancer risk, cholesterol control may be another primary prevention strategy for breast
cancer among post-menopausal women.
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The strength of this study includes the large sample size, which provided statistical power to
detect the associations of MetS and its individual components with overall breast cancer risk and
among whites. However, a limitation of the study is the lack of statistical power to detect significant
differences among blacks or by BMI and menopause groups. Future studies using large dataset across
cohorts, such as through large consortia like the Breast Cancer Screening Consortium, will be needed
to definitively evaluate MetS in relation to breast cancer risk among racially and ethnically diverse
groups and older women, and to corroborate findings across BMI levels. A second potential limitation
is that while the NIH-AARP cohort included only adults aged 50–71 years, pre-menopausal women
who were aged 50 years and above are likely not representative of pre-menopausal women in the
general population, and may represent a distinct group of women in late pre-menopause. A third
limitation of this study is that our definition of MetS relied on only four out of five components due to
lack of measured biomarker data on triglycerides and HDL in the NIH-AARP cohort and those with
missing values were different from those with complete data. In addition, blood pressure, cholesterol,
and diabetes data were based on self-reports, which may be vulnerable to misclassification, and only
measured at baseline. However, the prospective nature of the NIH-AARP data reduces the likelihood
of differential misclassification, so the bias is likely to result in underestimation of the true association.
The prospective design also reduced the risk of differential recall bias given that MetS components
were evaluated at baseline, and participants with data collected from proxy respondents at baseline
were excluded to further reduce measurement error. Nevertheless, our results are in line with other
published reports in this area and add important information regarding the role of central obesity in
the association between MetS and breast cancer risk in the U.S.
5. Conclusions
In conclusion, MetS was associated with increased risk of breast cancer, especially among
post-menopausal women regardless of obesity status, and the risk of breast cancer increased as
the number of MetS components increased. Larger datasets are needed to definitively evaluate the
role of MetS and individual components in risk of specific breast cancer subtypes, and in BMI and
menopause stratified groups. However, based on our findings and those of others, MetS may be a
useful target for lifestyle and/or clinical interventions as part of a comprehensive primary prevention
strategy for breast cancer.
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